← Russell 3000 cross-section

HUM HUMANA INC

Trailing twelve months to 2026-03-31 · as filed 2026-04-29, not restated
Financials

Scale

Market cap
$47.0bn
Revenue TTM
$137.2bn
Net income TTM
$1.1bn
Free cash flow
$1.3bn
Composite score
22.3
Sector rank
#252

Valuation

P / E
41.6
EV / EBITDA
12.0
EV / sales
0.3
FCF yield
2.71%
Earnings yield vs 10-yr
-2.32pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
0.8%
EBITDA margin
2.4%
ROE
6.1%
ROIC
23.0%
Revenue growth
14.1%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

At June 30, 2026, approximately 4,118,700 members, or 64%, of our individual Medicare Advantage members were in value-based relationships under our integrated care delivery model, as compared to 3,542,300 members, or 68%, at June 30, 2025. • Net income attributable to Humana was $694 million, or $5.73 per diluted common share, and $545 million, or $4.51 per diluted common share, for the three months ended June 30, 2026 and 2025, respectively. Net income attributable to Humana was $1.9 billion, or $15.55 per diluted common share, and $1.8 billion, or $14.81 per diluted common share, for the six months ended June 30, 2026 and 2025, respectively. …HUMANA INC, 10-Q, period ended 2026-06-30, filed 2026-07-29

Read the full passage →